Certara (NASDAQ:CERT) Shares Gap Up to $10.70

Certara, Inc. (NASDAQ:CERT) gapped up prior to trading on Friday . The stock had previously closed at $10.70, but opened at $11.59. Certara shares last traded at $11.74, with a volume of 140,900 shares trading hands.

Analysts Set New Price Targets

CERT has been the topic of several research reports. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Friday. JMP Securities restated a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. Barclays cut their price target on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, June 28th. KeyCorp lowered their price objective on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Finally, Robert W. Baird dropped their target price on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $17.79.

Certara Stock Performance

The stock has a market cap of $1.90 billion, a P/E ratio of -30.18, a PEG ratio of 5.17 and a beta of 1.49. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The company’s 50-day simple moving average is $12.82 and its 200 day simple moving average is $15.16.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $93.31 million for the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The business’s revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share. As a group, sell-side analysts expect that Certara, Inc. will post 0.27 EPS for the current fiscal year.

Insider Activity at Certara

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 2.39% of the stock is owned by company insiders.

Institutional Trading of Certara

Hedge funds have recently made changes to their positions in the company. Mubadala Investment Co PJSC purchased a new stake in Certara in the 4th quarter worth about $169,135,000. Wasatch Advisors LP raised its position in shares of Certara by 23.4% in the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock valued at $88,056,000 after purchasing an additional 932,598 shares during the period. Norges Bank bought a new stake in shares of Certara in the fourth quarter valued at approximately $14,262,000. Daventry Group LP lifted its stake in shares of Certara by 153.0% during the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after buying an additional 791,405 shares in the last quarter. Finally, Geneva Capital Management LLC boosted its holdings in Certara by 15.1% in the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after buying an additional 579,349 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.